Cancer Drug Price Cuts Start Nov 9, Saving ₹3,502 Crore a Year
Cancer drug price cuts on 137 medicines take effect on 9 November 2026 as NPPA caps trade margins at 30%, saving patients about ₹3,502 crore a year.
Cancer drug price cuts on 137 medicines take effect on 9 November 2026 as NPPA caps trade margins at 30%, saving patients about ₹3,502 crore a year.
Delhi High Court bars NPPA from coercive steps against AstraZeneca Pharma India over ₹151 crore Symbicort inhaler overcharging claim until 11 January 2027.
NPPA has released revised MRPs for 543 anti-cancer brands and packs under its 30% trade margin cap, effective 9 November, with generics and biosimilars cut by up to 93% while brands such as Avastin, Keytruda and nivolumab see no change.
NPPA has clarified that cancer-drug packs already in the market need not be recalled or relabelled when 30% trade-margin-capped prices for 137 drugs take effect on 9 November, provided retailers charge the revised MRP.
A Supreme Court bench asked why the drug pricing system appears to work for manufacturers, cited a hospital charging Rs 1.3 lakh for a cancer injection with an Rs 11,000 dealer price, and reserved its order on petitions over medicine pricing and trade margins.
The National Pharmaceutical Pricing Authority (NPPA) has approved a 50% increase in the ceiling prices of 11 formulations for eight […]
In a bid to provide relief to patients who are contemplating to go for knee implants in coming months, the […]
Indian drug pricing watchdog National Pharmaceutical Pricing Authority (NPPA) has cut prices of 24 more essential medicines, including widely used […]
[This article was published in the August 2008 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
India News